PI
NAGE

PEAK6 Investments’s Niagen Bioscience NAGE Stock Holding History

PEAK6 Investments’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-98,765
Closed -$922K – 5892
2021
Q1 		$922K Buy
+98,765
New +$783K ﹤0.01% 2639

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PEAK6 Investments's NAGE Position: Q2 2021 in Review

PEAK6 Investments sold out of Niagen Bioscience (NAGE) in Q2 2021, closing a stake of 98,765 shares — an estimated $922K sold.

PEAK6 Investments first reported a position in NAGE in Q1 2021 and held it in 1 quarter. The position peaked at $922K in Q1 2021. 101 funds tracked by Wall St. Rank hold NAGE as of Q2 2021.

  • PEAK6 Investments reported no remaining Niagen Bioscience position as of Q2 2021 after selling out during the quarter.
  • PEAK6 Investments sold 98,765 Niagen Bioscience shares in Q2 2021, an estimated $922K.
  • PEAK6 Investments first reported a position in Niagen Bioscience in Q1 2021 and held it in 1 quarter.
  • PEAK6 Investments's Niagen Bioscience position peaked at $922K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2021.

Based on PEAK6 Investments's 13F filing for Q2 2021, filed 13 Aug 2021.